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Background:  The  balance  between  tumor  necrosis
factor-a (TNF-a ) and interleukin-10 (IL-10) is impor-
tant for immune homeostasis maintenance. Exuber-
ant production of TNF-a contributes to overwhelming
inflammatory response and tissue damage. But, com-
monly,  increase  in  TNF-a is  counterbalanced  by
simultaneous synthesis of an anti-inflammatory cyto-
kine  IL-10,  which  suppresses  production  of  many
activating and regulatory mediators.
Aims: In the present study, the relationships between
TNF-a and  IL-10  in  the  plasma  of  healthy  school-
children and cystic  fibrosis (CF) patients have been
investigated.
Methods: Blood  samples  were obtained from  12 CF
patients  with  chronic  pulmonary  disease  and  18
healthy  schoolchildren  vaccinated  with  live  atte-
nuated rubella vaccine. IL-10 and TNF-a were deter-
mined  in  the  plasma  samples  using  commercially
available enzyme-linked immunosorbent assay kits.
Results:  Before  vaccination,  most  healthy  children
(13 of 18) demonstrated superiority of pro-inflamma-
tory TNF-a over anti-inflammatory IL-10 (TNF-a /IL-10
>  1).  In  these  subjects,  a  significant  positive  linear
association  between  the  cytokine  values  has  been
found. Vaccine challenge resulted in a marked reduc-
tion  of  TNF-a /IL-10  ratios.  In  addition,  a  disap-
pearance of correlation between the cytokine values
was observed. Such disturbance was related to exu-
berant elevation of the IL-10 levels after inoculation.
On the contrary, in CF individuals, plasma cytokine
values  remained  in  strong  linear  association  inde-
pendently of TNF-a or IL-10 predominance. No spikes
in the plasma levels of IL-10 in CF patients during a
6-month observation period have been revealed.
Conclusions: There were no fundamental differences
between CF and healthy children in the regulation of
TNF-a and IL-10 secretion. Thus, immune quiescence
seemed to  be associated with  the  predominance  of
TNF-a ,  whereas  immune  disturbance  was  charac-
terized  by  IL-10  superiority.  The  only  abnormality
that  was  found  in  CF  patients  consisted  of  their
inability to produce unlimitedly IL-10 in response to
antigen stimuli.
Key  words:  Tumor  necrosis  factor-a ,  Interleukin-10,
Inflammatory response, Cystic fibrosis, Vaccination
Introduction
Challenge  with  infectious  agents  or  their  products
provoke early secretion of regulatory cytokines includ-
ing tumor necrosis factor-a (TNF-a ) and interleukin-10
(IL-10). These cytokines are produced by the activated
macrophages and play opposite roles in both innate
and specific immune response.1,2 TNF-a upregulates
production of  other pro-inflammatory cytokines by
the  immune  and  nonimmune  cells3–6,  augments
leukocyte adhesion and promotes cell migration into
the tissue space.7 It facilitates antimicrobial activity of
neutrophils and macrophages but, in addition, poten-
tiates their tissue-damaging properties.8 Overzealous
production of the cytokine may have serious adverse
consequences  such  as  systemic  inflammation  and
septic shock.9,10But, commonly, rapid increase in  TNF-
a is counterbalanced by early and sustained expression
of anti-inflammatory IL-10.11This cytokine suppresses
production  of  important  activating  and  regulatory
mediators (including TNF-a ),2,12 inhibits the leukocyte
recruitment to sites of inflammation,13 decreases HLA-
DR expression by monocyte/macrophages and redu-
ces their Ag-presenting capacity.14 In addition, IL-10
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downregulates tissue injury.15,16
Until  recently,  there  was  very  little  existing  doc-
umentation on changes and regulation of the balance
of  TNF-a /IL-10  secretion  under  both  basal  and
immune-challenge  conditions.  The  relationships
between the cytokines have been most widely studied
in the context of sepsis syndrome. There are a lot of
reports  providing  a  protective  effect  of  IL-10  and
deteriorative TNF-a action during systemic inflamma-
tory  response  syndrome.17,18 However,  several
uncommon studies have suggested that overwhelm-
ing  expression  of  IL-10  may  contribute  to  sepsis-
induced immunosuppression and predispose the host
to  the  development  of  a  variety  of  nosocomial
infections;  in  particular,  bacterial  infection  of  the
lung.19,20 In this regard, change in TNF-a /IL-10 ratio
might be predictive of complications in patients with
inflammatory  diseases.  Indeed,  the  recent  study
focusing on TNF-a and IL-10 production in patients
with,  or  at  risk  of  developing,  adult  respiratory
distress  syndrome  (ARDS)  has  demonstrated  that
there  was  a  larger  ratio  of TNF-a to  IL-10  in  the
bronchoalveolar lavage fluid from patients with ARDS,
favoring  a  pro-inflammatory  process.21 Similarly,  a
significant  decrease of  IL-10  content in the lung  of
cystic fibrosis (CF) patients with chronic pulmonary
disease has been noticed.22
CF  is  an  autosomal  recessive  genetic  disorder,
which  occurs  with  mutation  in  the  CF  transmem-
brane conductance regulator (CFTR) gene. Abnormal
function  of  CFTR  results  in  obstructive  pulmonary
process due to accumulation of thick, viscous mucus,
which  leads  to  impaired  mucociliary  clearance.23
During the first years of life, young children with CF
are colonized and develop pneumonia secondary to
Staphylococcus aureus, Haemophilus influenzae or,
less  commonly,  Klebsiella  pneumoniae.24,25 Later,
the  patients  become  infected  with  Pseudomonas
aeruginosa.  Colonization  with  the  pathogens  ini-
tiates exuberant host immune response characterized
by a marked influx of neutrophils into the lung, and
elevation in inflammatory mediators such as TNF-a ,
IL-1b , IL-6, IL-8, and leukotriene B4.26,27 In this regard,
restricted  production  of  IL-10  in  CF  patients  may
contribute to exuberant immune response and lung
tissue damage.
In  the  present  study,  the  relationships  between
TNF-a and IL-10 in the plasma of healthy teenagers
and CF children with chronic lung disease have been
investigated.
Material and methods
Patient assessment
Twelve CF patients (mean age, 11.9 years) from the
Department of Cystic Fibrosis of the Research Center
for Medical Genetics (Moscow) were enrolled in the
study.  Cystic  fibrosis  was  diagnosed  by  increased
chloride  concentrations  (>  60mmol/l)  in  a  sweat
test  and  typical  clinical  symptoms  of  the  disease,
and/or detection of  mutation in  both CFTR alleles.
All  children  were  pancreatic  insufficient  and  suf-
fered  from  progressive  suppurative  pulmonary  dis-
ease. The patients were treated with  basic  therapy
(mucolytics, multivitamins, high calorie diet, micro-
spheric  enzymes)  and  nonsteroidal  anti-inflamma-
tory drug nimesulide in the daily dose of 3mg perkg
of  body  weight.  In  the  case  of  acute  pulmonary
exacerbation,  antibiotics  were  prescribed.  Individ-
uals  with  P.  aeruginosa infection  were  treated  by
cephalosporins  of  third  generation  in  combination
with  aminoglycosids  or  ciprofloxacin. The  patients
were seen every third month at the Department of
Cystic Fibrosis where clinical data and bacteriology
of bronchopulmonary infections had been recorded.
The  following  pulmonary  function  tests  were  per-
formed:  forced  expiratory  volume  in  1sec  (FEV1),
and forced vital capacity (FVC).
Blood samples were collected at the beginning of
the study, and then again 3 and 6 months later. Seven
patients (group A) with chronic P. aeruginosa infec-
tion and poor lung  function (FVC  and FEV1 <  70%
predicted)  were  evaluated  after  a  2-week  routine
antibiotic course. Five patients (group B) who demon-
strated relatively good lung function (FVC and FEV1 >
70% predicted) were examined at a time of well being
during  ordinary visit to the Department. The study
was approved by the Ethics Committee of the Federal
Children Hospital (Moscow, Russia).
Healthy schoolchildren
Blood  samples  were  obtained from  healthy  school-
children at Moscow Gabrichevsky Research Institute
of Epidemiology and Microbiology. The study group
included  18  children,  aged  11–13  years,  with  a
negative history of  rubella. All subjects had routine
physical examination and rubella serotesting. None of
the  participants  were  seropositive.  Children  were
vaccinated with live attenuated rubella vaccine Rudi-
vax® (Pasteur Merieux). No vaccine-related adverse
effects were noted. Heparinized blood was collected
before vaccination then again 1 week and 1 month
later.  The  subjects  had  no  personal  or  immediate
history of CF and no evidence of illness at the start of
or  during  the  study.  The  investigation  has  been
performed as a part of the special research program
‘Vaccination  against  rubella’  and  supported  by  the
Ministry of Health of Russian Federation.
Blood collection
Blood was collected in tubes with heparin (25IU/ml)
by venopuncture.
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Plasma samples were harvested and analyzed for IL-10
and TNF-a by  enzyme-linked  immunosorbent  assay
(ELISA) techniques with commercially available kits,
which were designed to measure the ‘total’ (bound
and unbound) amount of the cytokines (Cytimmune
Science Inc, MD, USA). The lower limits of detection
for the both assays were 0.195ng/ml.
Statistical analysis
Statistical  analysis  was  performed  using  non-para-
metric Wilcoxon tests. Relationships between TNF-a
and  IL-10  were  investigated  by  multiple  regression
analysis. The TNF-a concentration was considered as
the independent variable, and the IL-10 concentration
as the  dependent one.  Student’s t-test  was  used to
evaluate the regression coefficient.
Results
TNF-a and IL-10 in plasma of CF patients and
healthy children
Fig. 1 illustrates the individual variations in TNF-a and
IL-10 levels measured from normal children and CF
patients. As expected, we found a marked elevation in
plasma cytokine concentrations in healthy individuals
following rubella vaccination. In CF subjects, plasma
TNF-a levels were situated within a similar range as
compared with healthy children before immunization.
TNF-a /IL-10 balance in normal and CF children
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FIG. 1. Cytokine concentrations in the plasma of healthy children and CF patients. Plasma samples were assayed for TNF-a (A)
and IL-10 (B) by ELISA. The individual values of CF patients are the means of all results during 6 months of the observation
period. Median values are indicated by the lines. Each dot represents one subject. A two-sample Wilcoxon test was used to
compare the cytokine levels in healthy group before and after vaccine administration: TNF-a (A), p1,2 = 0.32, p1,3 = 0.001; IL-10
(B), p1,2 = 0.27, p1,3 = 0.038. Differences between CF patients and healthy children were analyzed using the unpaired Wilcoxon
test: TNF-a (A), p1,4 = 0.55; IL-10 (B), p1,4 = 1). Note that in response to rubella vaccination, both cytokines in the plasma of
healthy subjects were elevated and significantly exceeded the levels measured from CF patients: TNF-a (A), p2,4 = 0.037, p3,4
= 0.003; IL-10 (B), p2,4 = 0.0001, p3,4 = 0.0006.Mean values of the cytokine were 1.10 ± 0.21ng/ml in
children with CF and 1.61  ±  0.30ng/ml  in  healthy
individuals;  no  significant  difference  was  noted
between the groups (p = 0.32). With regard to IL-10,
mean values were 0.83 ± 0.06ng/ml in CF and 2.58 ±
0.84ng/ml in healthy children; no difference between
the groups was detected (p= 1). At the same time, both
TNF-a and IL-10 levels in CF children were much lower
than the cytokine values found in the plasma of healthy
subjects after rubella vaccination (all p < 0.04).
Ratio of TNF-a to IL-10 in the plasma of healthy
individuals and CF patients
The relative concentrations of plasma TNF-a and IL-10
in healthy children and CF patients were calculated
(Table 1). Prior to vaccination, the cytokine ratios in
healthy individuals were widely varied ranging from
0.14 to 23.33 (median value, 1.56). After inoculation,
the ratio of TNF-a /IL-10 was found to be significantly
decreased. Median values of the cytokine ratio were
0.65  on  day  7  and  0.52  on  day  30  following
vaccination (p = 0.05 and 0.02, respectively). In CF
patients, the ratio of TNF-a /IL-10 was at intermediate
value (1.09), which was not significantly different to
that of the healthy children before vaccination (p =
0.34). At the same time, in  comparison with vacci-
nated children, the cytokine ratio in CF subjects was
significantly  elevated  (both  p <  0.004).  Table  2
displays the semi-annual changes of TNF-a /IL-10 ratio
in  CF  patients.  Dependent  on  pulmonary  function
failure and disease severity, the patients were divided
into two groups. Group A (n = 7) showed poor lung
function (FVC and FEV1 < 70% predicted) and severe
pulmonary  disease. Group  B  (n =  5)  demonstrated
relatively good lung function (FVC and FEV1 > 70%
predicted)  and  mild  disease  severity.  A  significant
difference in the cytokine ratio between the groups
has been observed (p = 0.03). In group B, all the ratios
were > 1 except for a case associated with vaccina-
G. V. Shmarina et al.
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Table 1.  TNF-a /IL-10 ratios  in healthy children  and  young
cystic fibrosis patients
Healthy children
Subject
number
Before
vaccination
7 days
after
30 days
after
CF patients
Patient
number
1 1.56 0.89 1.26 1 0.52
2 9.33 0.65 0.43 2 0.79
3 0.14 0.77 0.43 3 1.31
4 1.60 0.62 0.48 4 0.69
5 6.44 0.97 0.48 5 1.24
6 4.03 0.32 0.06 6 1.02
7 0.99 0.83 0.56 7 1.03
8 0.64 0.94 0.77 8 1.82
9 1.12 0.26 ND 9 1.11
10 0.69 ND 0.90 10 1.06
11 1.46 0.24 0.56 11 1.73
12 0.32 0.27 0.63 12 2.37
13 1.22 0.28 0.45
14 6.79 65.69 ND
15 0.20 0.30 0.27
16 23.33 0.67 4.86
17 3.84 ND ND
18 13.03 ND ND
Median 1.51 0.65 0.52 1.09
p 0.05 0.02 0.341
0.003*
0.004**
The individual parameters of CF patients are the median values of the
results during 6 months of observation.
*Compared  with  the  parameters  of  healthy  children  1  week  after
rubella vaccination.
**Compared with healthy subjects on day 30 after inoculation.
Table 2. Semi-annual changes of TNF-a /IL-10 ratios in CF patients
CF
patients
Patient
number
TNF-a /IL-10 ratio
Month 0 Month 3 Month 6 Median
Group A 1* 0.52 0.60 0.47 0.52
(FVC < 70% 2** 0.79 0.92 0.76 0.79
predicted) 3 2.14 0.88
† 1.31 1.31
4 1.47 0.69 0.57 0.69
5 0.57 1.49 1.24 1.24
6 0.89 1.02 1.47 1.02
7 1.03 0.83
‡ 1.50 1.03
Mean ± m 1·06 ± 0·22 0·92 ± 0·11 1·05 ± 0·16 0·94 ± 0·11
Group B 8 1.56 1.82 1.92 1.82
(FVC > 70% 9 0.83
‡ 1.11 1.32 1.11
predicted) 10 1.20 1.06 0.79
† 1.06
11 6.04 1.73 1.68 1.73
12 2.8 1.60 2.37 2.37
Mean ± m 2·49 ± 0·95 1·46 ± 0·16 1·62 ± 0·27 1·62 ± 0·18
p 0.10 0.02 0.07 0.03
*The patient demonstrated a significant lung function failure in the end of the study.
**The patient died 2 months after finishing the study.
† Children were examined 2 weeks after acute lung exacerbation.
‡ Subjects were evaluated 2 weeks after vaccination against influenza (group A) and poliomyelitis (group B).tion and an incidence related to acute virus respira-
tory infection. In group A, individual values of TNF-
a /IL-10  ratio  fluctuated  about  1  and  were  clearly
lower than in group B.
Relationships between plasma levels of TNF-a
and IL-10 in healthy children and CF patients
The  data  indicate  that  the  cytokine  ratios  were  at
much  reduced  levels  in  vaccine-challenge  subjects
(including two vaccinated CF patients) as well as in
CF patients after acute lung exacerbation. At the same
time, these parameters were significantly elevated in
the  most  healthy  children  before  vaccination  (see
Table 1)  and in CF subjects during periods of well
being  (see Table 2).  In  the following,  two different
situations are considered. The first is associated with
the  incidences  when  TNF-a /IL-10  >  1  (immune
quiescence), the second related to cases when TNF-
a /IL-10  <  1  (immune  disturbance). Multiple  regres-
sion  analysis  has  been  performed  to  examine  the
relationships between the plasma cytokine levels. IL-
10  was  considered  as  a  dependent  parameter,
whereas TNF-a was independent. As can be seen in
Fig. 2A, there was a significant positive linear associa-
tion between the plasma cytokine levels in 13 healthy
children, who showed TNF-a /IL-10 > 1, before vac-
cine application (r = 0.94, p = 0.000002). A similar
result  has  been  obtained  in  CF  patients  with  high
cytokine ratios (r = 0.62, p = 0.002). At the same time,
no  correlation  has  been  noted  in  healthy  children
after immunization (Fig. 2B). However, when we did
not  take into account subject  number  6,  who  had
demonstrated the only spike in IL-10 plasma level, a
strong  positive  association  between  the  cytokine
values was found in other 11 children 1 month after
vaccination (r = 0.65, p = 0.03). With regard to CF
patients  with  low  cytokine  ratios,  they  showed  a
significant positive linear association (r = 0.89, p =
0.0002).
Discussion
In  recent  years,  it  has  become  evident  that  pro-
inflammatory cytokines are involved in the induction
of  IL-10  by  stimulated  monocyte.28,29 It  has  been
suggested that TNF-a is able to primarily regulate IL-10
transcription through  stimulation  of  activating  pro-
tein-1 recognizing by IL-10 promoter.30 Later, Foey et
al. hypothesized  that  IL-10  production  requires  at
least  two  signals;  the  first  is  provided by  lipopoly-
saccharide  (or  its  physiologic  equivalent),  and  the
second  by  endogenous TNF-a and/or  IL-1b .31 Fur-
thermore, circulating TNF-a and IL-1b are powerful
inducers  of  brain-mediated  anti-inflammatory
response. They  can  directly  stimulate  the  hypotha-
lamic–pituitary–adrenal  axis  and  enhance  sympa-
thetic  nerve  system  activity,  resulting  in  glucocor-
ticoid  and  catecholamine  secretion  that  limits
pro-inflammatory cytokine production and stimulates
IL-10 releasing.32,33
Changes  in  TNF-a /IL-10  ratios  that  have  been
observed in healthy children after rubella vaccination
are  in  accordance  with  the  current  concept  of
inflammatory response control. Thus, before vaccina-
tion,  most  healthy  children  (13  of  18)  exhibited
relatively  high  cytokine  ratios  (TNF-a /IL-10  >  1),
demonstrating  predominance  of  pro-inflammatory
TNF-a over anti-inflammatory IL-10. In these subjects,
a significant positive linear association between the
cytokine levels has been found. Rubella vaccination
and associated stress were bound to result in cate-
cholamine and corticosteroid releasing that promoted
IL-10  synthesis.32 Besides,  auxiliary  sources of anti-
inflammatory IL-10 (such as liver, spleen and brain as
well)  might  be  activated.17,34 Thereafter,  on  day  7
after immunization,  a rise in  IL-10  passed ahead of
TNF-a expansion.  In  this  context,  a  significant
decrease in TNF-a /IL-10 ratios and the absence of the
correlation  between  the  cytokines  have  been
observed. On day 30 after rubella vaccination IL-10
still  predominated  over TNF-a ,  but  the  association
between  the  cytokine  concentrations  tended  to
recover and was described again by linear regression
model.
In CF patients, the plasma cytokine values seemed
to be in linear association independently of IL-10 or
TNF-a predominance. Furthermore, no spikes in the
levels  of  IL-10  in  CF  patients  during  a  6-month
observation  period  have  been  presently  observed.
This  is  in  agreement  with  previous  studies  that
revealed a significant decrease of IL-10 content in CF
lung as well as reduced ability of CF epithelial cells
and CD4+ T lymphocytes to produce this cytokine in
response to inflammatory stimuli.22,35,36 One of the
possible  reasons of  these  phenomena is  a  primary
CFTR defect resulting in an absent or diminished Cl–
secretory function of the cells in response to cAMP-
mediated agonists. The latter is known to exert a dual
regulatory function by enhancing IL-10 formation and
attenuating TNF-a synthesis.37
CFTR or even its first nucleotide binding fold act as
Cl–-specific pores in lipid bilayer.38,39Triggering of the
cAMP pathway (e.g. by the binding of epinephrine to
b -adrenergic receptor) stimulates adenylate cyclase to
form  cAMP  that  results  in  the  activation  protein
kinase A, which in turn phosphorylates the regulatory
domains of the CFTR Cl– channels and increases their
open probability.38,40 Another consequence of cAMP
pathway  triggering  is  a  stimulation  of  CFTR  gene
expression.41 There  are  segments  within  the  CFTR
promoter that resemble AP-1 and AP-2 binding sites, a
cAMP-response element, and glucocorticoid response
elements.41,42 In  this  context,  cellular  response  to
various  physiological  stimuli  (including  catechola-
mines and glucocorticoids) might be associated with
TNF-a /IL-10 balance in normal and CF children
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and/or with the increase in CFTR expression. In CF,
reduced  Cl– conductance  and,  as  a  consequence,
defective signaling through a cAMP-dependent path-
way may result in numerous abnormalities including
restricted  IL-10  production  by  the  immune  and
nonimmune cells.
According to common opinion, increase in produc-
tion of IL-10 and decrease in TNF-a secretion should
be salutary in CF patients, especially in those of them
who have experienced chronic P. aeruginosa infec-
tion and exuberant inflammatory response. However,
our  data  indicate  that  predominance  of  IL-10  over
TNF-a in  the  circulation  of  CF  patients  may  be
considered  an  unfavorable  sign.  Thus, TNF-a /IL-10
ratios in patients with chronic P. aeruginosa infection
and severe lung  function failure were clearly lower
than  in  patients  with relatively  good  lung  function
G. V. Shmarina et al.
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FIG. 2. Relationships between plasma TNF-a and IL-10 concentrations in normal children and CF patients. Multiple regression
analysis has been performed. IL-10 and TNF-a were supposed as dependent and independent parameters, respectively. (A) In
the case of TNF-a /IL-10 > 1 (immune quiescence), plasma cytokine concentration correlated with regression lines, which were
described by the equations: IL-10 = 0.76 ´ TNF-a – 0.21 (line 1, normal children before vaccination) and IL-10 = 0.27 ´ TNF-a +
0.45 (line 2, CF patients). (B) Under TNF-a /IL-10 < 1 (immune disturbance), regression models are described by the equations:
IL-10 = 2.20 ´ TNF-a + 1.28 (line 3, normal children 1 month after vaccination) and IL-10 = 1.53 ´ TNF-a – 0.07 (line 4, CF patients).
The encircled point demonstrates a spike in IL-10 plasma level of subject number 6 (see text).(see Table 2). Moreover, two patients (numbers 1 and
2) with extremely poor lung function had TNF-a /IL-10
<  1  for  all  6  months  of  the  observation.  Patient
number  1  experienced  a  significant  lung  function
failure (more than 20% predicted) and patient number
2 died 1 month after finishing the study.
In conclusion, there were no fundamental differ-
ences  between  CF  and  healthy  children  in  the
regulation  of TNF-a and IL-10 secretion under both
basal  and  immune-challenge  conditions.  Thus,
immune quiescence seemed to be associated with the
predominance  of TNF-a ,  whereas  immune  disturb-
ance was characterized by IL-10 superiority. The only
abnormality,  which was  found  in  CF patients,  con-
sisted in their inability to produce unlimitedly IL-10 in
response  to  antigen  stimuli.  This  phenomenon  is
assumed to be related to primary CF defect, resulting
in inadequate cAMP-dependent signaling.
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